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Progress in myasthenia gravis C W H HAVARD British Medical3Journal, 1977 , 2, 1008 -1011 Myasthenia is a syndrome of increased fatigability in striated muscle. It may occur with lesions of the central nervous system or with lesions of muscle. The muscle weakness in these disorders is usually persistent and unrelenting. Myasthenia gravis, however, is a disorder of neuromuscular function due to a reduction of available acetylcholine (AC) receptors at the neuromuscular junction. The muscle weakness is characteristically worse after effort and improved by rest. The patient starts to comb her hair and is unable to finish, or halfway through a meal finds that she can chew no longer. The muscle weakness has a characteristic distribution, the extraocular, bulbar, neck, limb girdles, distal limbs, and trunk muscles being affected in that order. The myasthenia responds to cholinesterase inhibitors, which enhance the effects of the limited supply of AC at the neuromuscular junctions, and the quick-acting anticholinesterase edrophonium (Tensilon) provides a useful diagnostic test for myasthenia gravis. The diagnosis is not difficult so long as the possibility is kept in mind. When the distribution of muscle weakness is atypical psychiatric disease is commonly and erroneously diagnosed.
The incidence of myasthenia gravis is about 1 in 30 000. There is a tendency to early remission but complete remissions are not prolonged and are rarely repeated. They usually occur in those patients with the ocular forms of the disease and within two years of its onset. Patients with the purely ocular form of myasthenia gravis do not commonly develop generalised myasthenia if symptoms remain confined to the extraocular muscles for more than a year, and this may be a distinct variety of the disease.
Immune aspects of myasthenia gravis
The thymus gland is histologically abnormal in myasthenia gravis.1 Its histological picture is similar to that of the thyroid in Hashimoto's disease, and this similarity first led Smithers2 to suggest that myasthenia gravis was an autoimmune disease. Serum complement concentrations fall with disease activity.3 When myasthenia gravis is associated with a thymic tumour, and this occurs in 10'",) of cases, the tumour always has an epithelial component, arising in a type of cell that in its early development resembles striated muscle and hence has been called a myoid cell. Electron microscopy of the myoid cell has, however, shown them to have ultrastructural characteristics of epithelial cells rather than of striated muscle fibres, though they undoubtedly have AC receptors on their surface. 4 Circulating antibodies to skeletal muscle and to myoid cells of the thymus are present in the sera of some patients. Bungarotoxin may be labelled with 125-I and is used as a specific molecular probe for the nicotinic AC receptor molecule. It interacts specifically and irreversibly with AC receptors and may thus be used to determine the number of AC receptor sites, the number of bungarotoxin-binding sites being proportional and perhaps equal to the number of AC receptor sites. Biopsy specimens of muscles from myasthenic patients disclose that these muscles have less than 3000 of the AC receptors found in normal neuromuscular junctions.'9 It might be argued that the reduction in AC receptors reflects an effect of anticholinesterase drugs on the receptors or be a secondary effect of the disease process rather than its primary cause. Identical end-plate changes, however, occur in untreated patients with myasthenia as in those who have received anticholinesterase drugs.2' Furthermore, it was not long before it was shown that there is a factor located in the serum globulins of myasthenic patients that blocks the binding of bungarotoxin to AC receptors at the normal human neuromuscular junction.2' 22 It was presumed that this factor in the serum of myasthenic patients had already bound to the AC receptor, thereby preventing bungarotoxin access. An autoimmune pathogenesis for myasthenia gravis seemed probable with the circulating antibody directed against the AC receptor. Further progress depended on isolating the antigen.
Interest in the AC receptor was intense, but the problem of purification seemed insoluble. Only minute amounts of AC exist at neuromuscular junctions, and a way to identify the receptor in extracts of homogenised muscle seemed difficult. Attempts had been made many years ago to produce an experimental myasthenia in animals using homologous muscle antigen, but the antigen contained so little AC protein that these efforts were not successful. The electric organs of electric fish are densely innervated to enable the amount of ions passing through AC receptors to generate several hundred volts. Despite the fact that some electric eels contain 40 00 of their body weight as electric organ, there are only a few milligrams of receptor, Purification presented formidable problems, particularly as it was not obvious how to identify a molecule responsible for regulating ion permeability of cell membranes in extracts of homogenised muscle. By coupling cobra toxin to agarose beads the minute amounts of solubilised receptor were bound and Lindstrom was able to isolate the AC receptor from the rest of the homogenised muscle.9
The few milligrams of receptor isolated by Lindstrom were used to raise antibodies in the rabbit. A few weeks after immunisation with AC receptor the rabbits became weak and died. They had developed antibodies to the electric eel AC receptor that cross-reacted with their own AC receptor. Furthermore, this muscle weakness could be transiently overcome with anticholinesterase drugs.9 This disease is now called experimental autoimmune myasthenia gravis. It has been induced in several different species, including the monkey, in which the clinical features of ptosis closely mimic human myasthenia gravis.' The disease has also been induced in rats by immunisation with syngenetic AC receptor and the ensuing myasthenia is associated with the formation of circulating antibodies to AC receptors that reduce the number of available receptors.2' That the circulating antibodies are the cause of the disease is proved by the fact that the serum of rats immunised with AC receptor can cause the disease when injected into normal animals, and the histological changes at the neuromuscular junction are similar."
Experimental autoimmune myasthenia gravis has, however, been most closely studied in the rat in which it develops in two phases.
About a week after immunisation with AC receptor there is an initial stage of acute severe muscle weakness from which they recover and about three weeks later they develop a more insidious persistent weakness that is fatal within a few weeks. Electron microscopic studies have shown that the first phase is associated with invasion of the neuromuscular junction by macrophages and a breakdown of the postsynaptic membrane at sites where AC receptor is most concentrated. In the later chronic phase the number of AC receptors is reduced. The area of the postsynaptic membrane is decreased and its folded structure is simplified.2.; It would seem that the circulating antibody to AC receptor damages the receptors and reduces their competence. Phagocytosis follows and the amount of AC receptor is reduced. Thus both a reduction in the total amount of AC receptor and the formation of antibody-AC receptor complexes both contribute to the impairment of neuromuscular transmission. It appears that some regeneration of AC receptor can take place and the ability to synthesise new receptor will have an important effect on the prognosis.2X
Nevertheless, despite the increasing evidence that a circulating antibody damages the postsynaptic AC receptor experimental myasthenia is T-cell dependent for it will not develop in thymectomised animals and it can be passively transferred with cells.21; Also, the acute lesion at the myoneural junction in the experimental disease shows lymphocyte infiltration, characteristic of a cell-mediated immune response.2" Recently a high concentration of cell-mediated immunity to purified AC receptor has been shown in human myasthenia gravis and an association noted between disease activity and the concentration of cell-mediated immunity to receptor. It does not seem likely that the cellular response is secondary to damage to the neuromuscular junction as it does not occur in amyotrophic lateral sclerosis in which breakdown of the neuromuscular junction regularly occurs.2 Clinical experience in man also implicates the T cells in myasthenia. Both thymectomy and thoracic duct drainage deplete T cells and improve the disease. The answer probably lies in the immunological condition whereby B cell function is sustained by helper T cells.
THE HUMAN DISEASE
In 1974 it was shown that a circulating globulin in the serum of individuals with myasthenia blocked the binding of bungarotoxin to the AC receptor extracted from denervated rat skeletal muscle.2' Recently the passive transfer of human serum fractions from individuals with myasthenia gravis has induced the disease in mice. 12 The active serum fraction was identified as IgG. Furthermore, there was a rough correlation between the patient's clinical state and the potency of the serum factor in producing myasthenic features in the test animals, although disparities were seen in individual cases. Thoracic duct drainage is beneficial in myasthenia gravis, and reinfusion of the gammaglobulin fraction causes clinical deterioration. 2 Nevertheless, undoubtedly there is a myasthenia-producing IgG circulating in the blood of patients with myasthenia gravis. The action of this myasthenia-inducing IgG was influenced by the complement system for in the absence of C3 its effect was considerably lessened. Deficiency of C5 did not affect the results.
In about 90",, of people with myasthenia gravis there are circulating antibodies to AC receptor. These antibodies have also been shown in babies with neonatal myasthenia. They do not occur in patients with other diseases of neuromuscular function, such as amyotrophic lateral sclerosis and the EatonLambert syndrome. There is, however, no close correlation between antibody titre and the severity of the disease in myasthenia gravis.
The antibody titres fall after thymectomy, and indeed there is an inverse relationship between antibody titre and the interval after thymectomy. 2 9 A fall in antibody titre has also been reported after remissions induced by corticosteroids.24 This suggests that clinical improvement is associated with a fall in antireceptor antibody titre that decreases over several years. It is, however, unlikely that thymectomy removes a major source of antibody as the titre should then fall more quickly. Thymectomy may therefore remove an antigenic stimulus or may cause a gradual decrease in T lymphocytes necessary for antibody formation by B lymphocytes. A fall in circulating T lymphocytes has recently been shown in myasthenic patients after thymectomy,3" and this appears to be associated with an increase in the number of null cells, which are immature T cells needing thymic hormone to complete their development.
ROLE OF THE THYMUS
Undoubtedly great advances have been made in understanding the pathogenesis of myasthenia gravis. The immunological basis of the disease is beyond question but the role of the thymus, though fundamental to the disease, has not precisely been defined. Its importance is twofold. The fact that stem cells in the thymus can be induced to differentiate into striated muscle clones suggested the possibility that abnormal induction signals might occur in man in response to pathological changes in the thymus, and Wekerle and Ketelsen34 have recently proposed a hypothesis for the pathogenesis of myasthenia gravis. They suggest that primitive intrathymic stem cells are induced by abnormal stimuli to differentiate into myogenic cells. Then immunologically competent T cells start an immune reaction against these newly differentiated myogenic cells. Sensitised T cells then leave the thymus and become killer T cells infiltrating the neuromuscular junction and destroying it or cooperate with B cells as helper cells to form antibodies to the AC receptor. The pathogenesis is under genetic control both at the differentiation of T cells to myogenic cells and at the stage of immune responsiveness of the lymphocytes to these atypical muscle cells.
Medical treatment
Neostigmine and pyridostigmine are the basis of the medical treatment of myasthenia gravis. Ambenonium is occasionally used. Edrophonium has no place in treatment as its action is so short. These drugs are water-soluble and hence do not cross lipid barriers readily. They are thus distributed in the extracellular space and do not enter the central nervous system. Anticholinesterase drugs are, however, in no sense a cure and have no influence on the primary cause of the disease. They act by inhibiting the action of cholinesterase, which normally destroys AC: they are active by mouth but may if necessary be given parenterally.
When given at regular intervals during the day muscle strength can usually be restored to an adequate even if not normal level.
The dose of anticholinesterase drugs that gives the maximum therapeutic response must be established. This may.not restore muscle strength to normal, and the patient must often learn to live with some degree of disability. Most myasthenic patients can be improved only up to a certain level. Increasing the dose of drugs above the maximum response level in the forlorn hope of improving physical activity will produce the opposite effect, and progressive muscle weakness may finally end in a cholinergic crisis. The dose-response curve for anticholinesterase compounds has a rapid fall-off once the peak is reached. This may be because to some extent these agents may occupy the AC receptors and if present in excess prevent the normal action of AC. Overdosage thus not only increases the quantity of AC at the neuromuscular junction but also reduces the number of free receptors available for its effect. Myasthenic patients, like any other individuals, are subject to the fatigue of mental and physical strain, and the temptation to increase the dose of medication to counter such physiological fatigue must be resisted. Intercurrent infection may also cause deterioration of myasthenia but here the cautious and carefully supervised increase in dosage is justified. Neostigmine is given in a dose of 15 mg four-hourly or more often if necessary. It is effective within 30 minutes. The optimum frequency of administration must be decided and then the precise dose determined. When given parenterally a dose of 0 5 mg equals 15 mg by niouth. There are two varieties of peripheral cholinergic activity. Muscarine activity affects smooth muscle and glandular tissue while nicotinic activity affects autonomic ganglia and neuromuscular junctions. The cholinesterase inhibitors enhance both the muscarine and the nicotinic effects of AC. As muscarine activity affects smooth muscle and exocrine glands it is manifest by abdominal colic, diarrhoea, nausea, salivation, and lachrymation. Atropine may reduce these side effects. These symptoms, however, usually indicate overdosage, and for this reason it is unwise to prescribe atrophine routinely.
Pyridostigmine (Mestinon) has the advantage of more prolonged action, and it is rarely necessary to give it more often BRITISH MEDICAL JOURNAL 15 OCTOBER 1977 than four-hourly. It does, however, take longer to act. A dose of 60 mg equals 15 mg neostigmine. A dose of pyridostigmine of 60 mg four times daily should be used initially and the size of the dose increased until the maximum benefit is obtained. Patients who tend to be weak on awakening benefit from a dose of the quicker-acting neostigmine with the first dose of pyridostigmine. Patients with myasthenia gravis tend to develop anxiety over the disease. Everyday activities depend on taking tablets. The patient is thus inclined to increase the dose even when the fatigue is of emotional origin. Not only does emotional distress commonly aggravate myasthenia gravis but increasing the dose of anticholinergic drugs above the maximum response level may aggravate the muscle weakness and even provoke a cholinergic crisis.
NON-CHOLINESTERASE INHIBITORS
Drugs other than cholinesterase inhibitors have a place in treating myasthenia gravis. The beneficial effect of ephedrine has long been recognised, though the response is rarely striking. A dose of 30 nmg, however, thrice daily should be tried if the response to anticholinesterase agents is inadequate. Hypokalaemia aggravates muscle weakness so that potassium supplements may be useful.
The response to corticosteroids is often dramatic. 35 A myasthenic crisis may result from a natural deterioration of the disease or it may be precipitated by infection or surgery. The symptoms are due to a relative deficiency of AC and may usually be corrected by increasing doses of an anticholinesterase. A cholinergic crisis, on the other hand, is the result of excessive doses of cholinesterase inhibitors, and the treatment demands withholding these drugs. Both these crises present with severe weakness leading to paralysis. The differential diagnosis may be difficult but 10 mg edrophonium intravenously will usually enable the correct diagnosis to be made. If the crisis is cholinergic no such improvement occurs, and indeed the position may deteriorate. The action of the drug is so short that any deterioration due to increased anticholinesterase activity is unlikely to have any serious consequence. One of the difficulties that may arise after edrophonium is that one muscle group may become stronger and another weaker. It is therefore important that emphasis should be placed on the essential bulbar and respiratory muscles rather than the less essential ocular and limb muscles.
VALUE OF THYMECTOMY
Thymectomy is increasingly important in managing patients with myasthenia gravis. The risks of thymectomy are now small provided the operation is undertaken in a centre with good facilities for intensive care and in a unit with experience of the operation. The incidence of remission increases with the number of years after thymectomy. Complete remission or substantial improvement may be expected in 800 of patients without a tumour of the thymus, though it may take three to five years before the benefits of operation are apparent.42 Older patients are less likely to benefit from thymectomy but respond well to corticosteroids. In patients with a tumour early operation is also indicated but the prognosis is worse. With the exception of those with the purely ocular form of the disease, most patients with myasthenia should be offered thymectomy.
The earlier the operation is undertaken in the course of the disease the better the results.44 I am grateful to my surgical colleague, M J Lange, for the benefit of his counsel and experience.
